Apomorphine-induced pathway perturbation in MPP<sup>+</sup>-treated SH-SY5Y cells

Apomorphine (APOM) is a non-selective dopamine agonist for Parkinson’s disease (PD). It also offers protection against oxidative stress. Thus, it has been used for treating advanced PD patients who do not respond to levodopa or other dopamine agonists. However, side effects such as orthostatic hypot...

Full description

Bibliographic Details
Main Author: Jin Hwan Do
Format: Article
Language:English
Published: AIMS Press 2017-07-01
Series:AIMS Molecular Science
Subjects:
Online Access:http://www.aimspress.com/Molecular/article/1549/fulltext.html
Description
Summary:Apomorphine (APOM) is a non-selective dopamine agonist for Parkinson’s disease (PD). It also offers protection against oxidative stress. Thus, it has been used for treating advanced PD patients who do not respond to levodopa or other dopamine agonists. However, side effects such as orthostatic hypotension, nausea, and fibrotic nodules at the site of APOM injection have been reported after long-term use of APOM in PD patients. To secure the use of APOM for PD treatment without side effect, it is essential to understand the molecular mechanism involved in the action of APOM in PD. In this study, gene expression profile changes by APOM in a PD cell model, i.e., MPP<sup>+</sup>-treated SH-SY5Y cells, were measured at six time points (0, 3, 6, 9, 12, and 24 h) after APOM treatment using a commercial whole-genome expression array. A total of 2249 genes showed significant and differential expression profile. Pathways significantly affected by APOM were estimated using signaling pathway impact analysis (SPIA). In addition, differentially regulated regions within each affected pathway were identified with covariance analysis using a structure equation model.<br />
ISSN:2372-0301